Current status and research advances of patient–spouse stigma in breast cancer: a narrative review
Frontiers in Oncology · 20.11.2026 · 16
DOI: 10.3389/fonc.2026.1993088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Yao Zheng und 3 weiteren Autor:innen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Breast cancer is the most commonly diagnosed cancer among women globally. Treatment options for breast cancer vary according to disease stage, tumor characteristics and clinical indications, and may include radical mastectomy and chemotherapy. While appropriate treatments can improve survival outcomes for selected patients, diagnosis and long-term therapy bring considerable psychosocial challenges to patients and their spousal caregivers. Patients frequently experience heightened disease-related stigma resulting from physical discomfort, body image disturbances, and adverse treatment effects. Meanwhile, spouses of breast cancer patients may experience affiliated stigma. This paper reviews evidence regarding stigma among breast cancer patients and their spouses, to provide evidence-based references for targeted clinical psychosocial interventions.
Zitieren
APA
Zheng, Y., Zhong, C., Chen, B., & He, J. (2026). Current status and research advances of patient–spouse stigma in breast cancer: a narrative review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1993088
Vancouver
Zheng Y, Zhong C, Chen B, He J. Current status and research advances of patient–spouse stigma in breast cancer: a narrative review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1993088
BibTeX
@article{Zheng2026,
author = {Zheng, Yao and Zhong, Chunchang and Chen, Birong and He, Jinlan},
title = {Current status and research advances of patient–spouse stigma in breast cancer: a narrative review},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1993088}
}
EUVIMED